Komori
Stella Pharma (4888) · RiskMaterialisedLatest Occurring Fact (2026-08-07): "Mitigated"

Quality and Supply Continuity Risks Associated with Third-Party Contract Manufacturers

First written in FY2021. 5 of 10 entries say "Materialised", first in FY2026-H1. Latest entry: 2026-08-07.

10entries
6years
6from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2021 – FY20222021: 120212022: 120222023: 020232024: 020242025: 120252026: 72026
Same theme, other companies
Risk of insufficient supply capacity and shutdowns at outsourced production partnersA theme 65 companies write about · 67 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2024: 10 of 32 companies on the "Worse" side.

15 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 65 companies compared. The sentences above are computed from all 65.
Full recordFilings, disclosures and news, newest first
  1. FY2026MaterialisedAnnual report

    「As stated in the notice concerning the suspension of transactions with a major business partner published on 9 September 2025, we suspended transactions with the contract manufacturer for Steboronin®, our product under development, because it entered bankruptcy proceedings on 5 September 2025.」

    The previously identified risk to supply continuity, namely the business failure of the contract manufacturer, actually occurred. Production is being transferred to a new contract manufacturer and approval procedures are under way, but the possibility of an impact depending on the progress of the transfer remains.
  2. FY2026-H1MaterialisedAnnual report

    「As stated in the notice concerning the suspension of transactions with a major business partner published on 9 September 2025, we suspended transactions with the contract manufacturer for Steboronin®, our product under development, because it entered bankruptcy proceedings on 5 September 2025.」

    The previously disclosed risk of a contract manufacturer's business failure actually occurred, requiring transactions to be suspended and production to be transferred.
  3. FY2022RestatedAnnual report

    「If a contract manufacturer becomes insolvent or has its business license revoked due to violations of laws and regulations, we may be forced to change contract manufacturers. As selecting an alternative company and completing manufacturing, validation and an application for partial approval changes for the pharmaceutical require a certain period, this may have a material effect on our financial position and operating results.」

    The company continues to identify the risk of production delays due to quality issues, supply continuity concerns and business failures at external contract manufacturers, among other factors.
  4. FY2021First statedAnnual report

    「If a contract manufacturer suffers a disaster or other unforeseen event, such as damage to its manufacturing facilities, or if production lines are shut down or business suspension orders are imposed due to deficiencies in the manufacturer's production or quality control systems or violations of laws and regulations, product quality or stable supply may be disrupted.」

    The company identifies supply disruptions caused by disasters affecting contractors, deficiencies in quality control, business suspensions and business failures, among other factors.
Moved together

"Operating Losses and Negative Operating Cash Flow Due to Upfront Investment" moved the same way as this thread, in the same document, in 5 of its 10 moves.

52★12
  1. ★This thread
  2. 1Operating Losses and Negative Operating Cash Flow Due to Upfront Investment5×
  3. 2Stable Supply Through Dual-Sourcing of Raw Materials and Inventory Management2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Stella Pharma yet. It last moved in the Occurring Fact of 2026-08-07: "Mitigated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Quality and Supply Continuity Risks Associated with Third-Party Contract Manufacturers | STELLA PHARMA CORPORATION (4888) | Komori